New York State Psychiatric Institute
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, New York State Psychiatric Institute sits in the top decile of US sponsors by registered trial count (#99 of 15,742 sponsors by registered trial count).
New York State Psychiatric Institute: 364 sponsored US clinical trials, 12 recruiting.
New York State Psychiatric Institute sponsors 364 registered US clinical trials on ClinicalTrials.gov, 12 of them currently recruiting, and 296 completed. 80 of these trials are in Phase 3-4 (later-stage) and 152 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 10 trials.
Top-decile sponsor footprint
New York State Psychiatric Institute ranks in the top decile of sponsors by registered trial count (#99 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
296 of 342 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
364 total, page 6 of 8
Imaging the Dopamine Systems in Bulimia Nervosa
NCT01493362
Study of Adderall-XR for the Treatment of Adult Attention Deficit Hyperactivity Disorder and Cocaine Dependence
NCT00553319
Buprenorphine Maintenance Treatment of Opioid Dependence in Primary Care: A Randomized Clinical Trial
NCT00684554
Motivation to Exercise in People With Anorexia Nervosa
NCT00961428
A Relapse Prevention Program for Reducing Relapse and Fear of Food in People With Anorexia Nervosa
NCT00627341
Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Panic Disorder With Comorbid Major Depression
NCT00521352
Behavioral Naltrexone Therapy for Promoting Adherence to Oral Naltrexone vs Extended Release Injectable Depot Naltrexone
NCT00577408
Abuse Liability of Suboxone Versus Subutex
NCT00710385
Does Dual Therapy Hasten Antidepressant Response?
NCT00519428
Neurocircuitry of Autism- fMRI and Transcranial Magnetic Stimulation Studies
NCT01553240
Treating Depression With Transcranial Direct Current Stimulation (tDCS)
NCT00481988
A Pilot Study Assessing EmSam in Bipolar Depression
NCT00535262
A Placebo-Controlled Study of Mixed Amphetamine Salts and Topiramate for the Treatment of Cocaine Dependence
NCT00421603
Gabapentin Treatment of Benzodiazepine Abuse in Methadone Maintenance Patients
NCT00420771
Effect of Memantine Versus Bupropion on Smoking Relapse in Nicotine-Dependent Individuals - 3
NCT00136786
Early Detection and Prevention of Mood Disorders in Children of Parents With Bipolar Disorder
NCT00338806
Interpersonal Psychotherapy for Depressed Adolescents Engaging in Non-suicidal Self-injury
NCT00401102
Cognitive Behavior Therapy for Adolescents With Bulimia
NCT00974038
Risperidone or Cognitive-Behavioral Therapy for Improving Medication Treatment for Obsessive-compulsive Disorder
NCT00389493
Pre-Treatment Positron Emission Topography Scanning for Increasing Success in Antidepressant Treatment
NCT00456014
STAR*D Alcohol: Treatment of Depression Concurrent With Alcohol Abuse
NCT00369746
Duloxetine for Chronic Depression: a Double-blind Study
NCT00360724
Dichotic Listening as a Predictor of Medication Response in Depression
NCT00404755
Imaging the Neurobiology of a Behavioral Treatment for Cocaine Dependence
NCT00376558
Treatment of Children With ADHD Who do Not Fully Respond to Stimulants
NCT00279409
Modafinil for Treatment of Fatigue in ALS Patients
NCT00614926
Study of Buprenorphine Maintenance Treatment for Opioid Dependence in Primary Care
NCT00471042
Treatment of Depersonalization Disorder With Transcranial Magnetic Stimulation (TMS)
NCT00529217
Effect of Baclofen on Marijuana Withdrawal and Relapse
NCT00373295
Combined Treatment for Alcohol-Dependent Individuals With PTSD
NCT00262223
Open-label Ziprasidone Study for Psychosis Treatment in Adolescents
NCT00421954
Mirtazapine for Treating Cocaine Dependent Individuals Who Also Suffer From Depression
NCT00249444
Effects of Smoked Marijuana on Risk Taking and Decision Making Tasks
NCT00373399
Memantine Plus Es-citalopram in Elderly Depressed Patients With Cognitive Impairment
NCT01876823
Effects of Vigabatrin on Cocaine Self-Administration
NCT00373581
Cognitive Behavioral Therapy Plus Motivational Interviewing for Treatment of Obsessive-Compulsive Disorder
NCT00316316
Fluoxetine and Bupropion to Treat Patients With Depression and Alcoholism
NCT00449007
Duloxetine Treatment in Elderly With Dysthymia
NCT01852383
Effectiveness of Culturally Based Congruent Care in Treating Hispanics With Major Depressive Disorder
NCT00247195
Prescription Opioid Abuse Among Pain Patients: Predictors of Relapse
NCT01967641
Atomoxetine for Treating Marijuana-Abusing Adolescents Who Have Attention Deficit Hyperactivity Disorder
NCT00142961
Effectiveness of Olanzapine Versus Placebo in Treating Outpatients With Anorexia Nervosa
NCT00692185
Antepartum Study on Use of Interpersonal Psychotherapy at 3 New York City Site
NCT00251043
Effect of Lofexidine and Oral THC on Marijuana Withdrawal and Relapse
NCT00373503
Memantine and Naltrexone Treatment for Opioid Dependence
NCT00125515
Motivating Factors That Play a Role in Bulimia Nervosa
NCT00304174
Effects of Aripiprazole on Cocaine Craving and Self-Administration
NCT00373880
Effectiveness of Baclofen in the Treatment of People With Bulimia Nervosa or Binge Eating Disorder
NCT00320047
Determining the Response to Sipping Beverages Without Swallowing in People With Eating Disorders
NCT00353548
A Trial of Inflammatory Markers, Depressive Symptoms, and Heart Disease
NCT00208117
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 51 |
| Phase 2 | 101 |
| Phase 3 | 14 |
| Phase 4 | 66 |
Therapeutic Areas
What is open in the New York State Psychiatric Institute pipeline
12 recruiting of 364 indexed (3% open); 296 completed (81%).
Phase mix: 80 late (III/IV) vs 152 early (I/II) (early-phase heavy).
Top condition: Depression (10 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
New York State Psychiatric Institute: open-pipeline peers nationwide
Peers matched on 364 registered trials and 3% open enrollment, not the therapeutic-area sidebar.
New York State Psychiatric Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 364 trials (± recruiting share)
- Roswell Park Cancer Institute · 365 trials · 16% recruiting
- UNC Lineberger Comprehensive Cancer Center · 366 trials · 22% recruiting
- University of California, Irvine · 368 trials · 20% recruiting
- Northwell Health · 370 trials · 22% recruiting
Sponsors near 3% open enrollment (± trial volume)
- Biotronik · 3% recruiting · 30 trials
- Charles Drew University of Medicine and Science · 3% recruiting · 30 trials
- Kyntra Bio · 3% recruiting · 30 trials
- Halozyme Therapeutics · 3% recruiting · 31 trials
Related
What to do with this New York State Psychiatric Institute page
364 registered trials is a research-attention snapshot, not an endorsement of New York State Psychiatric Institute or any single study.
- 12 of New York State Psychiatric Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Depression is the condition New York State Psychiatric Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. New York State Psychiatric Institute pipeline card: 364 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.